This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Libby Edwards, MD; Stephen B. Tucker, MD; Douglas Perednia, MD; Kenneth A. Smiles, PhD; Eugene L. Taylor, MS; Daniel J. Tanner, MD; Edwin Peets, PhD

Arch Dermatol. 1990;126(8):1029-1032.

Abstract
• Intralesional interferon alfa-2b has been proven effective in the treatment of basal cell carcinomas. Because nine injections over a 3-week period have been necessary to produce clinically significant cure rates, a sustainedrelease protamine zinc chelate interferon formulation has been developed. In this study, 65 basal cell carcinomas were treated in one of two dosing schedules with intralesional sustained release interferon alfa-2b (10 million IU per injection). Thirty-three patients received a single injection and 32 patients received one injection per week for 3 weeks. At study week 16, 80% of evaluable tumors treated with three injections and 52% treated with one injection were cured histologically. Two patients discontinued injections because of side effects. A sustainedrelease protamine zinc preparation of interferon alfa-2b shows promise as a practical, effective, and cosmetically elegant treatment for basal cell carcinoma.

(Arch Dermatol. 1990;126:1029-1032)

Author Affiliations
From the University of Arizona College of Medicine, Tucson (Drs Edwards and Perednia); the University of Texas Medical School, Houston (Dr Tucker); and Schering-Plough Research, Kenilworth, NJ (Drs Smiles, Tanner, and Peets and Mr Taylor). Dr Smiles is now with Oclassen Pharmaceuticals Inc, San Rafael, Calif.

Footnotes
Accepted for publication January 8, 1990.

Presented at the 47th annual meeting of the American Academy of Dermatology, Washington, DC, December 5, 1988.

Reprints not available.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Interventions for basal cell carcinoma of the skin: systematic review
Bath-Hextall et al.
BMJ 2004;329:705.
ABSTRACT | FULL TEXT  

The Interferons: Mechanisms of Action and Clinical Applications
Baron et al.
JAMA 1991;266:1375-1383.
ABSTRACT  

Presentation of Sebaceous Carcinoma and Dermatofibrosarcoma Protuberans Subsequent to Intralesional Interferon Alfa-2b for the Treatment of In Situ Squamous Cell Carcinoma
Wagner and Sanchez
Arch Dermatol 1991;127:272-272.
ABSTRACT  

Interferon: Coming of Age
Greenway and Cornell
Arch Dermatol 1990;126:1080-1082.
ABSTRACT